Saye H. Khoo
Plus aucun poste en cours
Profil
Saye H.
Khoo worked as a Clinical Director at Delphic Diagnostics Ltd.
and as a Pharmacology Professor at The University of Liverpool.
Anciens postes connus de Saye H. Khoo
| Sociétés | Poste | Fin |
|---|---|---|
Delphic Diagnostics Ltd.
 Delphic Diagnostics Ltd. Medical/Nursing ServicesHealth Services Delphic is a specialist laboratory company with world-leading capabilities in pharmacology and pharmacogenetics. It was the first company in the world to offer an integrated diagnostics and biomarker service in HIV and is now applying that model in hepatitis. It has particular expertise in infectious diseases, including capabilities in study design and in method development and transfer, and a growing clinical trials portfolio. It is planning to apply its expertise to other therapy areas. Delphic is growing, organically and by acquisition, into a specialist biomarker and companion diagnostics company able to support the growing demand for personalised medicine in clinical therapy and in drug development. Its laboratories are certified to ISO, GCLP, CAP and CLIA. It has global reach via its own laboratories in the UK and partner laboratories in Italy, Spain, Greece and Argentina. | Directeur Technique/Scientifique/R&D | 03/10/2012 |
The University of Liverpool
 The University of Liverpool Other Consumer ServicesConsumer Services The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Delphic Diagnostics Ltd.
Delphic Diagnostics Ltd. Medical/Nursing ServicesHealth Services Delphic is a specialist laboratory company with world-leading capabilities in pharmacology and pharmacogenetics. It was the first company in the world to offer an integrated diagnostics and biomarker service in HIV and is now applying that model in hepatitis. It has particular expertise in infectious diseases, including capabilities in study design and in method development and transfer, and a growing clinical trials portfolio. It is planning to apply its expertise to other therapy areas. Delphic is growing, organically and by acquisition, into a specialist biomarker and companion diagnostics company able to support the growing demand for personalised medicine in clinical therapy and in drug development. Its laboratories are certified to ISO, GCLP, CAP and CLIA. It has global reach via its own laboratories in the UK and partner laboratories in Italy, Spain, Greece and Argentina. | Health Services |
